<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">JPP</journal-id>
         <journal-id journal-id-type="hwp">spjpp</journal-id>
         <journal-title>Journal of Pharmacy Practice</journal-title>
         <issn pub-type="ppub">0897-1900</issn>
         <issn pub-type="epub">1531-1937</issn>
         <publisher>
            <publisher-name>SAGE Publications</publisher-name>
            <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.1177/0897190012451913</article-id>
         <article-id pub-id-type="publisher-id">10.1177_0897190012451913</article-id>
         <article-categories>
            <subj-group subj-group-type="heading">
               <subject>Review Articles</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Benign Prostatic Hyperplasia</article-title>
            <subtitle>Implications for Pharmacologic Treatment and Perioperative Care</subtitle>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Leedahl</surname>
                  <given-names>David D.</given-names>
               </name>
               <degrees>PharmD, RPh</degrees>
               <xref ref-type="aff" rid="aff1-0897190012451913">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Vo</surname>
                  <given-names>Phil H.</given-names>
               </name>
               <degrees>PharmD, RPh</degrees>
               <xref ref-type="aff" rid="aff1-0897190012451913">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Maxson</surname>
                  <given-names>Pamela M.</given-names>
               </name>
               <degrees>PhD, RN, CNS</degrees>
               <xref ref-type="aff" rid="aff2-0897190012451913">2</xref>
            </contrib>
            <contrib contrib-type="author" corresp="yes" xlink:type="simple">
               <name name-style="western">
                  <surname>Lovely</surname>
                  <given-names>Jenna K.</given-names>
               </name>
               <degrees>PharmD, RPh, BCPS</degrees>
               <xref ref-type="aff" rid="aff1-0897190012451913">1</xref>
               <xref ref-type="corresp" rid="corresp1-0897190012451913"/>
            </contrib>
         </contrib-group>
         <contrib-group content-type="issue">
            <contrib contrib-type="guest-editor" xlink:type="simple">
               <name name-style="western">
                  <surname>Tackett</surname>
                  <given-names>Kimberly L.</given-names>
               </name>
               <degrees>PharmD, MBA, CDE, BCPS (AQID)</degrees>
            </contrib>
            <contrib contrib-type="guest-editor" xlink:type="simple">
               <name name-style="western">
                  <surname>McKeever</surname>
                  <given-names>Andrea L.</given-names>
               </name>
               <degrees>PharmD, BCPS</degrees>
            </contrib>
         </contrib-group>
         <aff id="aff1-0897190012451913">
            <label>1</label>Pharmacy Services, Mayo Clinic, Rochester, MN, USA</aff>
         <aff id="aff2-0897190012451913">
            <label>2</label>Department of Nursing, Mayo Clinic, Rochester, MN, USA</aff>
         <author-notes>
            <corresp id="corresp1-0897190012451913">Jenna K. Lovely, Pharmacy Services, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. Email: <email xlink:type="simple">lovely.jenna@mayo.edu</email>
            </corresp>
         </author-notes>
         <pub-date pub-type="epub-ppub">
            <month>2</month>
            <year>2013</year>
         </pub-date>
         <volume>26</volume>
         <issue>1</issue>
         <issue-title>Pulmonary Medicine: Part II</issue-title>
         <fpage>52</fpage>
         <lpage>58</lpage>
         <permissions>
            <copyright-statement>© The Author(s) 2012</copyright-statement>
            <copyright-year>2012</copyright-year>
            <copyright-holder content-type="sage">SAGE Publications</copyright-holder>
         </permissions>
         <abstract>
            <p>This review provides an update on the treatment of benign prostatic hyperplasia and the pharmacologic considerations for perioperative care. By age 85 years, approximately 90% of men have prostate histologic characteristics consistent with benign prostatic hyperplasia. Pharmacologic treatment with an alpha<sub>1</sub> receptor antagonist may reduce symptoms and, when given in combination with a 5-alpha-reductase inhibitor, may decrease the risk of urinary retention and the need for surgical intervention. Transurethral resection of the prostate has been the historical standard when surgical intervention is indicated. However, recent evidence suggests that Holmium laser enucleation of the prostate may have similar efficacy with less risk of complications and with decreased catheterization time. Prostatic urological operations may have perioperative complications, including urethral bleeding, acute urinary retention, urinary tract infection, urge incontinence, and venous thromboembolism. Pharmacist recommendations for the appropriate use of laxatives, antibiotics, anticoagulation, and urinary antispasmodics are key components of perioperative management. Surgical interventions improve symptoms but may have complications, providing the pharmacist an opportunity to improve perioperative care.</p>
         </abstract>
         <kwd-group>
            <kwd>surgery</kwd>
            <kwd>urology</kwd>
            <kwd>perioperative care</kwd>
            <kwd>postoperative complications</kwd>
            <kwd>prostatic hyperplasia</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="section1-0897190012451913">
         <title>Introduction</title>
         <p>Approximately 50% of men have prostate histologic characteristics consistent with benign prostatic hyperplasia (BPH) by age 60 years.<sup>
               <xref ref-type="bibr" rid="bibr1-0897190012451913">1</xref>
            </sup> At age 85 years, their percentage increases to 90%. More than 14 million men in the United States currently have some type of lower urinary tract symptoms (LUTS), and most have these symptoms secondary to BPH.<sup>
               <xref ref-type="bibr" rid="bibr2-0897190012451913">2</xref>
            </sup> This prostate disorder is characterized by overgrowth of prostate tissue, urethral lumen narrowing, and subsequent blockage of urine flow. Although not usually life threatening, LUTS have a substantial impact on a patient’s quality of life and must be managed appropriately. Active surveillance, pharmacologic therapy, and surgical intervention are all used to treat and prevent the progression of BPH.<sup>
               <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
            </sup>
         </p>
         <p>Historically, transurethral resection of the prostate (TURP) has been the reference surgical procedure for most patients who have moderate to severe LUTS and in whom pharmacologic therapy has failed. Emerging surgical therapies involving laser technology have shown comparable efficacy to TURP. Prevention and identification of surgical complications, which occur most frequently in the perioperative and late postoperative phases,<sup>
               <xref ref-type="bibr" rid="bibr4-0897190012451913">4</xref>
            </sup> require great vigilance from the surgical pharmacist to provide optimal outcomes for this patient population.</p>
      </sec>
      <sec id="section2-0897190012451913">
         <title>Pathophysiology of BPH</title>
         <p>The exact cause of BPH remains unclear. However, investigators have proposed that LUTS have both a static and a dynamic source.<sup>
               <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
            </sup> A proliferative mechanism on the tissue causes the gland to grow in size, creating urethral blockage as the prostate pushes against the urethra. Concurrently, an increase in prostatic smooth muscle tone creates troublesome resistance within the enlarged gland by diminishing urethral lumen diameter. Combating the static component of prostatic growth requires early intervention and serves primarily to prevent disease progression. Decreasing smooth muscle tone also appears to have treatment value, primarily in symptom relief.<sup>
               <xref ref-type="bibr" rid="bibr5-0897190012451913">5</xref>
            </sup>
         </p>
         <p>Over time, the static element of BPH (prostate growth) is driven by the conversion of testosterone into dihydrotestosterone by the enzyme 5-alpha-reductase. The pathophysiology of dihydrotestosterone hinges on its ability to stimulate prostatic tissue growth.<sup>
               <xref ref-type="bibr" rid="bibr6-0897190012451913">6</xref>
            </sup> When the prostate size increases, a mechanical blockage produces resistance within the urethra. If no intervention takes place, increased resistance to urinary flow may resolve, stabilize, or progress to bladder outlet obstruction (BOO).<sup>
               <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
            </sup> When 5-alpha-reductase can be inhibited effectively, serum dihydrotestosterone levels decline and may result in decreased prostate gland size over time.<sup>
               <xref ref-type="bibr" rid="bibr7-0897190012451913">7</xref>
            </sup> Clinically, low dihydrotestosterone levels do not necessarily result in symptom relief.</p>
         <p>The dynamic component in BPH—smooth muscle tone—is increased through excessive stimulation of the alpha<sub>1</sub>-adrenergic receptors, which are abundant in the prostatic capsule, bladder neck, and proximal urethra. Blocking these receptors allows nonvascular, smooth muscle relaxation in these areas, followed by a decrease in bladder pressure. As demand on the detrusor muscle to force urine through the obstructed passage decreases, normalization of bladder function may be possible.<sup>
               <xref ref-type="bibr" rid="bibr8-0897190012451913">8</xref>
            </sup> The consequences of untreated BOO include hydronephrosis, renal insufficiency, urinary retention, recurrent infection, and bladder decompensation.<sup>
               <xref ref-type="bibr" rid="bibr9-0897190012451913">9</xref>,<xref ref-type="bibr" rid="bibr10-0897190012451913">10</xref>
            </sup>
         </p>
      </sec>
      <sec id="section3-0897190012451913">
         <title>Diagnostics and Patient Symptoms</title>
         <p>According to the 2011 update of the American Urological Association (AUA) guidelines on the management of BPH, several diagnostic tests are recommended to guide LUTS management and the diagnosis of BPH.<sup>
               <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
            </sup> These tests include digital rectal examination, voiding frequency/volume report, urinalysis, and measurement of serum prostate-specific antigen. <xref ref-type="table" rid="table1-0897190012451913">Table 1</xref> contains a list of common patient symptoms consistent with BPH. To standardize the evaluation of LUTS and to aid in BPH severity categorization, the AUA developed its Symptom Index. To complete this assessment tool, the severity of 7 specific symptoms is rated on a scale of 1 to 5. A particular patient’s LUTS are considered mild for a total score of 2 to 7, moderate for 8 to 19, and severe for 20 to 35.<sup>
               <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
            </sup>
         </p>
         <table-wrap id="table1-0897190012451913" position="float">
            <label>Table 1.</label>
            <caption>
               <p>Lower Urinary Tract Symptoms.<sup>a</sup>
               </p>
            </caption>
            <graphic alt-version="no" alternate-form-of="table1-0897190012451913" position="float" xlink:href="10.1177_0897190012451913-table1.tif" xlink:type="simple"/>
            <table>
               <tbody>
                  <tr>
                     <td colspan="1" rowspan="1">Increased frequency of urination<list list-type="bullet">
                           <list-item>
                              <p>Need to urinate &lt;2 hours apart</p>
                           </list-item>
                        </list>
                     </td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Nocturia<list list-type="bullet">
                           <list-item>
                              <p>≥33% urine output at night</p>
                           </list-item>
                        </list>
                     </td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Hesitancy<list list-type="bullet">
                           <list-item>
                              <p>Need to push or strain to begin urination</p>
                           </list-item>
                        </list>
                     </td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Weak urinary stream<list list-type="bullet">
                           <list-item>
                              <p>Qmax &lt;10 mL/s</p>
                           </list-item>
                        </list>
                     </td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Urgency/urge incontinence<list list-type="bullet">
                           <list-item>
                              <p>Unable to postpone urination</p>
                           </list-item>
                        </list>
                     </td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Post void dripping</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Sensation of incomplete bladder emptying</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <fn id="table-fn1-0897190012451913">
                  <p>
                     <sup>a</sup> Data from McVary et al.<sup>
                        <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
                     </sup>
                  </p>
               </fn>
            </table-wrap-foot>
         </table-wrap>
         <p>Patients who have evidence of upper urinary tract injury presenting with renal insufficiency, gross hematuria, or bladder stones generally become candidates for surgical intervention. Surgery is also indicated for those with recurrent urinary tract infections or LUTS that do not respond adequately to other therapies. Surgical intervention may be considered early in symptomatic BPH, but the patient should be informed of the risks and benefits associated with the different treatment methods.<sup>
               <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
            </sup>
         </p>
      </sec>
      <sec id="section4-0897190012451913">
         <title>Pharmacologic Therapy</title>
         <sec id="section5-0897190012451913">
            <title>Overview</title>
            <p>Pharmacologic strategies generally antagonize the 2 established components of urethral narrowing secondary to BPH. The dynamic component of BPH is the overstimulation of prostatic smooth muscle, which results in contraction of the prostate around the urethral lumen. The static component of this disease is directly related to the excessive growth of prostatic tissue into the urethral space. An alpha-adrenergic blocker (alpha-blocker) may relax prostatic smooth muscle and alleviate symptoms. Alpha-blockers are typically associated with various adverse effects, including hypotension (less selective agents), dizziness, headache, abnormal ejaculation, fatigue, and rhinitis. Postural hypotension, orthostatic hypotension, and orthostasis are terms used to describe the clinically important blood pressure lowering associated with some alpha-blockers when standing up, most notably terazosin hydrochloride.<sup>
                  <xref ref-type="bibr" rid="bibr8-0897190012451913">8</xref>
               </sup> Use of a 5-alpha-reductase inhibitor (5-ARI) may provide benefit by depleting dihydrotestosterone, a hormone that facilitates prostate tissue growth.<sup>
                  <xref ref-type="bibr" rid="bibr11-0897190012451913">11</xref>
               </sup> The 5-ARIs have a relatively benign adverse effect profile, with impotence, abnormal ejaculation, and reduced libido occurring in approximately 4% to 8% of patients.<sup>
                  <xref ref-type="bibr" rid="bibr12-0897190012451913">12</xref>,<xref ref-type="bibr" rid="bibr13-0897190012451913">13</xref>
               </sup>
            </p>
            <p>Patients who are not bothered by LUTS or have an AUA Symptom Index score of less than 8 may use the strategy of watchful waiting as initial management. For those with moderate to severe LUTS secondary to BPH, initial therapy with an alpha-blocker is usually appropriate. Alfuzosin hydrochloride, doxazosin mesylate, tamsulosin hydrochloride, and terazosin hydrochloride are alpha-blockers with equal clinical effectiveness, but they differ in adverse effect profiles.</p>
         </sec>
         <sec id="section6-0897190012451913">
            <title>Alpha-Blockers</title>
            <p>Prazosin was the first selective alpha<sub>1</sub>-blocker investigated for the treatment of BPH.<sup>
                  <xref ref-type="bibr" rid="bibr8-0897190012451913">8</xref>
               </sup> However, prazosin is not widely used for LUTS/BPH treatment due to multiple daily dosing and adverse effects related to its blood pressure-lowering properties.<sup>
                  <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>,<xref ref-type="bibr" rid="bibr8-0897190012451913">8</xref>
               </sup> Long-acting alpha<sub>1</sub>-blockers, such as doxazosin and terazosin, have generic equivalents and may be reasonable, less costly choices in therapy.<sup>
                  <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
               </sup> Doxazosin and terazosin are indicated for BPH, as well as hypertension, and are generally taken once daily. Efficacy in the treatment of hypertension is due to their indiscriminate action at both the alpha<sub>1a</sub> (nonvascular smooth muscle) and the alpha<sub>1b</sub> (vascular smooth muscle) receptors. In addition to relaxing stromal smooth muscle of the prostate, alpha<sub>1a/b</sub>-blockers also cause relaxation in vascular smooth muscle and a subsequent lowering of blood pressure. Syncope and “first-dose” hypotension may occur with these agents, especially in the elderly population. Patients and heath care professionals should note the increased fall risk associated with the first several days of therapy. Therefore, gradual dosage titration, bedtime dosing, and blood pressure monitoring are warranted with these medications.<sup>
                  <xref ref-type="bibr" rid="bibr14-0897190012451913">14</xref>,<xref ref-type="bibr" rid="bibr15-0897190012451913">15</xref>
               </sup>
            </p>
            <p>Newer alpha<sub>1</sub>-blockers, such as alfuzosin, tamsulosin, and silodosin, have greater selectivity for alpha<sub>1a</sub>-adrenergic receptors and are not generally associated with the first-dose effect. However, nocturia may be problematic for some patients and thus require an earlier administration time. These agents were more costly until generic tamsulosin became available in 2010. The 2011 average wholesale price for tamsulosin was approximately $0.25/dose, making it the least expensive single agent for pharmacologic management of BPH.<sup>
                  <xref ref-type="bibr" rid="bibr16-0897190012451913">16</xref>
               </sup> 
               <xref ref-type="table" rid="table2-0897190012451913">Table 2</xref> provides additional information about the various pharmacologic therapies for BPH.<sup>
                  <xref ref-type="bibr" rid="bibr12-0897190012451913">12</xref>
                  <xref ref-type="bibr" rid="bibr13-0897190012451913"/>
                  <xref ref-type="bibr" rid="bibr14-0897190012451913"/>
                  <xref ref-type="bibr" rid="bibr15-0897190012451913"/>
                  <xref ref-type="bibr" rid="bibr16-0897190012451913"/>
                  <xref ref-type="bibr" rid="bibr17-0897190012451913"/>
                  <xref ref-type="bibr" rid="bibr18-0897190012451913"/>
                  <xref ref-type="bibr" rid="bibr19-0897190012451913"/>
                  <xref ref-type="bibr" rid="bibr20-0897190012451913"/>–<xref ref-type="bibr" rid="bibr21-0897190012451913">21</xref>
               </sup>
            </p>
            <table-wrap id="table2-0897190012451913" position="float">
               <label>Table 2.</label>
               <caption>
                  <p>Pharmacologic Options in the Treatment of Benign Prostatic Hyperplasia.<sup>a</sup>
                  </p>
               </caption>
               <graphic alt-version="no" alternate-form-of="table2-0897190012451913" position="float" xlink:href="10.1177_0897190012451913-table2.tif" xlink:type="simple"/>
               <table>
                  <thead>
                     <tr>
                        <th colspan="1" rowspan="1">Drug</th>
                        <th colspan="1" rowspan="1">Hypertension indication</th>
                        <th colspan="1" rowspan="1">Selectivity</th>
                        <th colspan="1" rowspan="1">Dose, initial/maintenance<sup>b</sup>
                        </th>
                        <th colspan="1" rowspan="1">Cost/day, 2010 AWP</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td colspan="1" rowspan="1">Alpha-blockers</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Alfuzosin hydrochloride extended release (Uroxatral)<sup>c</sup>
                        </td>
                        <td colspan="1" rowspan="1">No</td>
                        <td colspan="1" rowspan="1">Alpha<sub>1a</sub>
                        </td>
                        <td colspan="1" rowspan="1">10 mg/10 mg</td>
                        <td colspan="1" rowspan="1">$3.94</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Doxazosin mesylate (Cardura)<sup>c</sup>
                        </td>
                        <td colspan="1" rowspan="1">Yes</td>
                        <td colspan="1" rowspan="1">Alpha<sub>1a/b</sub>
                        </td>
                        <td colspan="1" rowspan="1">1 mg/1-8 mg</td>
                        <td colspan="1" rowspan="1">$0.59</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Doxazosin mesylate extended release (Cardura XL)<sup>c</sup>
                        </td>
                        <td colspan="1" rowspan="1">No</td>
                        <td colspan="1" rowspan="1">Alpha<sub>1a/b</sub>
                        </td>
                        <td colspan="1" rowspan="1">4 mg/4-8 mg</td>
                        <td colspan="1" rowspan="1">$1.93</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Silodosin (Rapaflo)<sup>d</sup>
                        </td>
                        <td colspan="1" rowspan="1">No</td>
                        <td colspan="1" rowspan="1">Alpha<sub>1a</sub>
                        </td>
                        <td colspan="1" rowspan="1">8 mg/8 mg<sup>e</sup>
                        </td>
                        <td colspan="1" rowspan="1">$3.94</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Tamsulosin hydrochloride (Flomax)<sup>c</sup>
                        </td>
                        <td colspan="1" rowspan="1">No</td>
                        <td colspan="1" rowspan="1">Alpha<sub>1a</sub>
                        </td>
                        <td colspan="1" rowspan="1">0.4 mg/0.4-0.8 mg</td>
                        <td colspan="1" rowspan="1">$0.25<sup>f</sup>
                        </td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Terazosin hydrochloride (Hytrin)<sup>c</sup>
                        </td>
                        <td colspan="1" rowspan="1">Yes</td>
                        <td colspan="1" rowspan="1">Alpha<sub>1a/b</sub>
                        </td>
                        <td colspan="1" rowspan="1">1 mg/2-20 mg</td>
                        <td colspan="1" rowspan="1">$1.60</td>
                     </tr>
                     <tr>
                        <td colspan="5" rowspan="1">5-Alpha-reductase inhibitor</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Dutasteride (Avodart)</td>
                        <td colspan="1" rowspan="1">No</td>
                        <td colspan="1" rowspan="1">Alpha-α-reductase types I and II</td>
                        <td colspan="1" rowspan="1">0.5 mg/0.5 mg</td>
                        <td colspan="1" rowspan="1">$4.06</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Finasteride (Proscar)<sup>c</sup>
                        </td>
                        <td colspan="1" rowspan="1">No</td>
                        <td colspan="1" rowspan="1">5-alpha-reductase type II only</td>
                        <td colspan="1" rowspan="1">5 mg/5 mg</td>
                        <td colspan="1" rowspan="1">$1.73</td>
                     </tr>
                     <tr>
                        <td colspan="5" rowspan="1">Combination product</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Dutasteride/ tamsulosin hydrochloride (Jalyn)<sup>e</sup>
                        </td>
                        <td colspan="1" rowspan="1">No</td>
                        <td colspan="1" rowspan="1">Alpha /5-alpha-reductase types I and II</td>
                        <td colspan="1" rowspan="1">0.5 mg dutasteride/0.4 mg tamsulosin (initial and maintenance)</td>
                        <td colspan="1" rowspan="1">$4.07</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <fn id="table-fn2-0897190012451913">
                     <p>Abbreviation: AWP, average wholesale price.</p>
                  </fn>
                  <fn id="table-fn3-0897190012451913">
                     <p>
                        <sup>a</sup> Data from Avodart,<sup>
                           <xref ref-type="bibr" rid="bibr12-0897190012451913">12</xref>
                        </sup> Proscar,<sup>
                           <xref ref-type="bibr" rid="bibr13-0897190012451913">13</xref>
                        </sup> Cardura,<sup>
                           <xref ref-type="bibr" rid="bibr14-0897190012451913">14</xref>
                        </sup> Hytrin,<sup>
                           <xref ref-type="bibr" rid="bibr15-0897190012451913">15</xref>
                        </sup> Uroxatral,<sup>
                           <xref ref-type="bibr" rid="bibr17-0897190012451913">17</xref>
                        </sup> Flomax,<sup>
                           <xref ref-type="bibr" rid="bibr18-0897190012451913">18</xref>
                        </sup> Rapaflo,<sup>
                           <xref ref-type="bibr" rid="bibr19-0897190012451913">19</xref>
                        </sup> Jayln,<sup>
                           <xref ref-type="bibr" rid="bibr20-0897190012451913">20</xref>
                        </sup> Red book: pharmacy’s fundamental reference,<sup>
                           <xref ref-type="bibr" rid="bibr21-0897190012451913">21</xref>
                        </sup> www.cardinal.com.<sup>
                           <xref ref-type="bibr" rid="bibr16-0897190012451913">16</xref>
                        </sup>
                     </p>
                  </fn>
                  <fn id="table-fn4-0897190012451913">
                     <p>
                        <sup>b</sup> All are single daily doses.</p>
                  </fn>
                  <fn id="table-fn5-0897190012451913">
                     <p>
                        <sup>c</sup> Generic availability.</p>
                  </fn>
                  <fn id="table-fn6-0897190012451913">
                     <p>
                        <sup>d</sup> Not in the 2011 update of the American Urological Association guidelines because of a lack of relevant published articles in peer-reviewed literature before the cutoff date.</p>
                  </fn>
                  <fn id="table-fn7-0897190012451913">
                     <p>
                        <sup>e </sup>Dose adjusted to 4 mg in moderate renal impairment.</p>
                  </fn>
                  <fn id="table-fn8-0897190012451913">
                     <p>
                        <sup>f</sup> Cost/day reflects 2011 AWP.</p>
                  </fn>
               </table-wrap-foot>
            </table-wrap>
         </sec>
         <sec id="section7-0897190012451913">
            <title>5-Alpha-Reductase Inhibitors</title>
            <p>Two 5-ARIs are currently indicated by the US Food and Drug Administration (FDA) for BPH. These agents are not known for symptom control but rather for decreased risk of acute urinary retention (AUR) and of the need for prostate-related surgery.<sup>
                  <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
               </sup> Although no efficacy data are available for direct comparison, 2 pharmacologic parameters differentiate these agents. Dutasteride inhibits both the type I and type II isoenzymes of 5-alpha-reductase, whereas finasteride inhibits the type II isoenzyme alone. The type II isoenzyme is found primarily in the prostate and reproductive tissues; the type I isoenzymes are found in the prostate, liver, and skin. This effectiveness may translate into a greater reduction of dihydrotestosterone from dutasteride therapy, but the clinical impact continues to be uncertain. In 43 men with BPH, 3 months of treatment with dutasteride at a dose of 0.5 mg daily resulted in a 94% decrease in serum dihydrotestosterone from baseline.<sup>
                  <xref ref-type="bibr" rid="bibr22-0897190012451913">22</xref>
               </sup> Conversely, 1 week of finasteride treatment in 63 men with symptomatic BPH at various finasteride doses (between 1 and 100 mg daily) showed a 70% decline in serum dihydrotestosterone.<sup>
                  <xref ref-type="bibr" rid="bibr21-0897190012451913">21</xref>
               </sup> In addition, the half-life of dutasteride is 5 weeks, compared with the 6- to 8-hour half-life of finasteride.<sup>
                  <xref ref-type="bibr" rid="bibr12-0897190012451913">12</xref>,<xref ref-type="bibr" rid="bibr13-0897190012451913">13</xref>
               </sup>
            </p>
            <p>Prescribers for patients who have difficulty with treatment adherence may consider dutasteride in the treatment armamentarium, whereas prescribers for patients who have persistent adverse effects may use this pharmacokinetic parameter to promote the use of finasteride.<sup>
                  <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
               </sup> We must note that the clinical significance of half-life differences for these agents has not been well investigated. In addition, the onset of action for 5-ARIs is much slower than for the alpha-blockers. It may take as much as 3 months of dutasteride therapy or 6 months of finasteride treatment to observe clinical effect, and no dosage titration is required for 5-ARIs because of a relatively mild adverse-effect profile and a wide therapeutic index. We emphasize that neither finasteride nor dutasteride should be administered to a woman or a child because of potential teratogenic effects. Women should use protective gloves when handling or administering 5-ARI medications.<sup>
                  <xref ref-type="bibr" rid="bibr12-0897190012451913">12</xref>,<xref ref-type="bibr" rid="bibr13-0897190012451913">13</xref>
               </sup>
            </p>
         </sec>
         <sec id="section8-0897190012451913">
            <title>Combination Therapy</title>
            <p>Combination therapy with an alpha-blocker and a 5-ARI has shown benefit in men at high risk for disease progression. Candidates for combination therapy typically are patients who have symptomatic BPH. The alpha-blocker may decrease LUTSs as the 5-ARI decreases prostate size over time.<sup>
                  <xref ref-type="bibr" rid="bibr23-0897190012451913">23</xref>,<xref ref-type="bibr" rid="bibr24-0897190012451913">24</xref>
               </sup> The decision to use monotherapy versus combination therapy must be a collaborative decision between the patient and the prescriber, weighing symptomatic control against the possibility of additional adverse effects.</p>
         </sec>
         <sec id="section9-0897190012451913">
            <title>Anticholinergics</title>
            <p>Anticholinergic agents may be considered as treatment alternatives or adjuncts in the management of predominantly irritative LUTS/BPH. Anticholinergics used in BPH exert antimuscarinic effects on the detrusor muscle of the bladder. Relaxation of the detrusor muscle leads to decreased bladder overactivity and may alleviate LUTS.<sup>
                  <xref ref-type="bibr" rid="bibr25-0897190012451913">25</xref>
               </sup> The 2011 update to the AUA guidelines recommends attaining a baseline post void residual (PVR) before initiating anticholinergics, using caution in patients with a PVR greater than 250 to 300 mL who may be at risk for AUR. Randomized clinical trial evidence, which has primarily evaluated the use of tolterodine tartrate in combination with alpha-blocker therapy, has not sufficiently demonstrated efficacy. However, benefit for some patients may exist.<sup>
                  <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
               </sup>
            </p>
            <p>Athanasopoulos et al<sup>
                  <xref ref-type="bibr" rid="bibr26-0897190012451913">26</xref>
               </sup> randomized 50 consecutive subjects with BOO and overactive bladder (OAB) to either tamsulosin hydrochloride 0.4 mg orally daily or the combination of tamsulosin plus tolterodine tartrate immediate-release 2 mg orally twice a day. At 3 months, the combination group demonstrated a statistically significant improvement in quality-of-life scores with no reported episodes of AUR.<sup>
                  <xref ref-type="bibr" rid="bibr26-0897190012451913">26</xref>
               </sup> Kaplan et al<sup>
                  <xref ref-type="bibr" rid="bibr25-0897190012451913">25</xref>
               </sup> randomly assigned 879 subjects with BPH and OAB to 1 of 4 groups: placebo, tolterodine tartrate extended-release 4 mg orally once a day, 0.4 mg tamsulosin hydrochloride orally once a day, or the combination of tolterodine plus tamsulosin for 12 weeks. At week 12, a significantly greater proportion of patients in the combination group reported treatment benefit over the 3 other groups. Changes in PVR, maximum urinary flow rate, and incidence of AUR did not differ significantly between groups.<sup>
                  <xref ref-type="bibr" rid="bibr25-0897190012451913">25</xref>
               </sup> Indeed, the trials summarized above indicate the actual risk of AUR with tolterodine tartrate may be exaggerated. Despite the potential benefit of anticholineric medications in BPH, adverse effects including dizziness, dry mouth, constipation, and AUR may be problematic and should be carefully monitored. Discussing the risks associated with anticholinergic therapy, particularly in elderly persons, is also important.</p>
         </sec>
         <sec id="section10-0897190012451913">
            <title>Complementary and Alternative Medicine</title>
            <p>Saw palmetto (<italic>Serenoa repens</italic>) and stinging nettle (<italic>Urtica dioica</italic>) are 2 dietary supplements which have been used as nonconventional therapy for LUTS/BPH. The 2011 update to the AUA guidelines does not currently recommend the use of any dietary supplement for BPH treatment.<sup>
                  <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
               </sup> Unless higher quality evidence becomes available, the use of dietary supplements or other phytotherapeutic agents for LUTS/BPH should not be advocated.</p>
         </sec>
      </sec>
      <sec id="section11-0897190012451913">
         <title>Surgical Options</title>
         <p>Surgery is generally indicated for men with symptomatic BPH or prostate cancer who have urinary tract injury (<xref ref-type="table" rid="table3-0897190012451913">Table 3</xref>). The 2011 update to the AUA guidelines suggests that some patients may appropriately consider surgical intervention sooner, depending on the clinical picture.<sup>
               <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
            </sup> Urinary tract injury may present in various renal and urinary dilemmas.<sup>
               <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
            </sup> Historically, TURP has been the surgical mainstay of symptomatic BPH treatment. However, the limitations of potential postoperative morbidities, indwelling catheter time, and hospital length of stay have threatened the contemporary status of TURP.<sup>
               <xref ref-type="bibr" rid="bibr27-0897190012451913">27</xref>
            </sup> During this procedure, a resectoscope and diathermy loop are introduced into the bladder through the penis. The prostate adenoma is then resected in strips and dropped into the bladder. After the capsule of the prostate is exposed, the strips are evacuated from the bladder with an irrigation solution. Hemostasis is restored using electrocautery, and a new epithelial surface develops during 6 to 12 weeks. TURP is indicated only for a prostate size less than 100 g. Open prostatectomy used to be the only reasonable option for men with a larger prostate. However, patients now have more options in the surgical management of BPH.<sup>
               <xref ref-type="bibr" rid="bibr28-0897190012451913">28</xref>
            </sup>
         </p>
         <table-wrap id="table3-0897190012451913" position="float">
            <label>Table 3.</label>
            <caption>
               <p>Indications for Invasive Therapy in Benign Prostatic Hyperplasia.<sup>a</sup>
               </p>
            </caption>
            <graphic alt-version="no" alternate-form-of="table3-0897190012451913" position="float" xlink:href="10.1177_0897190012451913-table3.tif" xlink:type="simple"/>
            <table>
               <tbody>
                  <tr>
                     <td colspan="1" rowspan="1">Hydronephrosis</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Renal dysfunction</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Urinary retention</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Recurrent infection</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Bladder decompensation</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Bladder caliculi</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Persistent gross hematuria</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <fn id="table-fn9-0897190012451913">
                  <p>
                     <sup>a</sup> Data from McVary et al.<sup>
                        <xref ref-type="bibr" rid="bibr3-0897190012451913">3</xref>
                     </sup>
                  </p>
               </fn>
            </table-wrap-foot>
         </table-wrap>
         <p>New surgical therapies for BPH have emerged in the past decade. Most of these procedures involve laser technology and have been labeled collectively <italic>minimally invasive surgical therapies</italic> (MISTs). These therapies have claimed advantages over TURP and open prostatectomy, but evidence to support their use over long-standing surgical treatments has been lacking until recently. A meta-analysis by Ahyai and colleagues<sup>
               <xref ref-type="bibr" rid="bibr4-0897190012451913">4</xref>
            </sup> in 2010 found that Holmium laser enucleation of the prostate (HoLEP), first introduced in 1992, is the only endoscopic procedure to date with proven superior efficacy to TURP. The HoLEP procedure is prostate size independent and may be used to remove prostates that were able to be removed only with open prostatectomy before its development.<sup>
               <xref ref-type="bibr" rid="bibr4-0897190012451913">4</xref>
            </sup> Holmium laser ablation of the prostate is a similar procedure, but it is designed for a prostate of less than 60g.</p>
         <p>HoLEP involves the insertion of a resectoscope into the penile urethra, visualization of anatomy, and laser enucleation of each prostatic lobe. Individually, each lobe is enucleated, dissected, separated, and inspected before being dropped into the bladder. The laser fiber and stabilizing catheter are removed, and a morcellator is inserted. This device decreases the enucleate size (through a cutting mechanism) as it vacuums the tissue out of the bladder. Hemostasis is accomplished simultaneously during laser enucleation.<sup>
               <xref ref-type="bibr" rid="bibr29-0897190012451913">29</xref>
            </sup>
         </p>
      </sec>
      <sec id="section12-0897190012451913">
         <title>Surgical Complications</title>
         <p>Ahyai and colleagues<sup>
               <xref ref-type="bibr" rid="bibr4-0897190012451913">4</xref>
            </sup> evaluated functional outcomes and complications associated with TURP and several of the most common MISTs. Twenty-three controlled trials, including more than 2245 patients randomly assigned between 1997 and 2009, were evaluated.<sup>
               <xref ref-type="bibr" rid="bibr4-0897190012451913">4</xref>
            </sup> For the scope of the present article, we use the findings for TURP and HoLEP.</p>
         <p>Surgical complications may be classified into 3 categories: intraoperative, perioperative, and late. The most common intraoperative complication in TURP procedures is bleeding requiring transfusions, occurring in 2% of cases. In 0.8% of TURP procedures, patients have a dilutional hyponatremia due to systemic absorption of the glycine irrigant used for the procedure. This condition is called <italic>transurethral resection syndrome </italic>(TUR syndrome) and may carry substantial clinical consequences if not managed appropriately.</p>
         <p>Nausea is typically the first symptom of hyponatremia secondary to TUR syndrome. However, as cerebral edema becomes a concern, neurologic symptoms, including confusion, twitching, seizures, hypotension, and transient visual disturbances, may develop and require intervention. Hypertonic saline, hemodialysis, and loop diuretics have all been used in the clinical management of TUR syndrome.<sup>
               <xref ref-type="bibr" rid="bibr4-0897190012451913">4</xref>,<xref ref-type="bibr" rid="bibr30-0897190012451913">30</xref>
            </sup> Perioperative complications are more frequent. AUR, clot retention, and urinary tract infection occur in about 4% to 5% of patients who undergo TURP. Life-threatening, late complications are rare after TURP. However, retrograde ejaculation may occur in up to 76% of patients at 6 months.<sup>
               <xref ref-type="bibr" rid="bibr29-0897190012451913">29</xref>
            </sup> Other late complications to note include bladder neck stricture (2%), urethral stricture (4%), and urgency (2.2%).<sup>
               <xref ref-type="bibr" rid="bibr4-0897190012451913">4</xref>
            </sup>
         </p>
         <p>Complications from HoLEP procedures are similar to TURP, with a few exceptions. Bladder injury may affect approximately 3% of patients because of accidental manipulation of the morcellator during tissue evacuation, a complication not observed with TURP. TUR syndrome is not associated with HoLEP because of the use of a normal saline irrigant. Late-occurring urgency (5.6%) and transient dysuria (1.2%) may be more frequent than in TURP. However, the percentages given in the analysis by Ahyai and colleagues<sup>
               <xref ref-type="bibr" rid="bibr4-0897190012451913">4</xref>
            </sup> were not compared for statistical significance. Mean urinary catheter time post-HoLEP is about 24 hours—a marked decrease from the post-TURP average of almost 3 days.<sup>
               <xref ref-type="bibr" rid="bibr4-0897190012451913">4</xref>
            </sup>
         </p>
         <sec id="section13-0897190012451913">
            <title>Perioperative Anticoagulation and Prophylaxis for Venous Thromboembolism</title>
            <p>Some debate surrounds the perioperative use of warfarin sodium and low-molecular-weight heparin (LMWH) in urological surgery. Although some specific recommendations were made for this patient population by Meyer and colleagues<sup>
                  <xref ref-type="bibr" rid="bibr31-0897190012451913">31</xref>
               </sup> in 2003, the 2012 American College of Chest Physicians (ACCP) guidelines<sup>
                  <xref ref-type="bibr" rid="bibr32-0897190012451913">32</xref>
               </sup> provide perioperative anticoagulation strategy in common surgical scenarios. The clinician should attempt to separate patients into risk strata for both bleeding and thromboembolism. Although a validated tool for bleeding risk stratification is lacking, urologic procedures involving prostate resection are considered “high risk” for bleeding in the setting of anticoagulant and antiplatelet drug use. Therefore, the clinical pharmacist should assess bleeding risk using the perioperative anticoagulant or antiplatelet properties and its proximity to surgery. A tool for stratifying thromboembolic risk is provided in the 2012 ACCP guidelines. Therefore, patients are typically characterized as low, intermediate, or high risk of thrombosis.<sup>
                  <xref ref-type="bibr" rid="bibr32-0897190012451913">32</xref>
               </sup>
            </p>
            <p>Patients who are at low risk for venous thromboembolism (VTE; eg, VTE &gt;3 months ago, atrial fibrillation with no stroke history) should stop warfarin approximately 5 days before surgery and allow their international normalized ratio to reach a normal value. These patients may then resume warfarin therapy at 12 to 24 hours postoperatively. Those patients who have an intermediate risk of VTE (eg, VTE 1 to 3 months ago, history of aortic valve placement) may stop warfarin treatment approximately 5 days before surgery and initiate LMWH therapy 2 days before the procedure as the international normalized ratio returns to normal. Although Meyer and colleagues<sup>
                  <xref ref-type="bibr" rid="bibr31-0897190012451913">31</xref>
               </sup> recommend giving the last dose of LMWH at 12 hours before urologic surgery, the 2012 ACCP guidelines<sup>
                  <xref ref-type="bibr" rid="bibr32-0897190012451913">32</xref>
               </sup> for perioperative management of anticoagulation suggests withholding the last dose of LMWH before surgery when a twice-daily regimen is used. Administering half of the daily dose of LMWH the morning before surgery is recommended for patients using a once-daily regimen.<sup>
                  <xref ref-type="bibr" rid="bibr32-0897190012451913">32</xref>
               </sup>
            </p>
            <p>TURP and other MISTs carry a high risk of postprocedure bleeding. However, warfarin therapy may be resumed when hemostasis is established, or generally the evening of surgery. For the majority of patients, the full effect of warfarin anticoagulation does not occur until 3 to 5 days of therapy. When bridging is required, administering the first dose of LMWH during a warfarin bridging protocol at 48 to 72 hours postprocedure is recommended for these patients after hemostasis is secured. For patients with high risk of VTE (eg, patients with mitral valve, stroke history, multiple risk factors, or VTE in the past month), an intravenous infusion of unfractionated heparin may be titrated to full anticoagulation (activated partial thromboplastin time ratio, 1.5-2.5), discontinued 6 hours before surgery, and recommenced 12 hours postoperatively if hemostasis has been established. For high-risk patients, warfarin bridging with either unfractionated heparin or LMWH is recommended.<sup>
                  <xref ref-type="bibr" rid="bibr31-0897190012451913">31</xref>,<xref ref-type="bibr" rid="bibr32-0897190012451913">32</xref>
               </sup> Perioperative oral anticoagulation may not be discontinued in all patients with urologic surgery.<sup>
                  <xref ref-type="bibr" rid="bibr33-0897190012451913">33</xref>
               </sup> However, this medical situation is rarely encountered in clinical practice.</p>
            <p>Most transurethral operations, including TURP, require only early ambulation for VTE prophylaxis when completed in the outpatient setting. Intermittent pneumatic compression and graduated compression stockings are acceptable methods of VTE prevention for hospitalized patients and those with increased risk. Advanced age (&gt;40 years), active malignancy, prior VTE, trauma, immobility, major surgery, and blood disorders are risk factors for perioperative VTE in urological surgery. Many, additional risk factors for VTE are not addressed in this article. Depending on the clinical picture, low-dose unfractionated heparin or LMWH may be indicated when high-risk patient parameters are met.<sup>
                  <xref ref-type="bibr" rid="bibr32-0897190012451913">32</xref>,<xref ref-type="bibr" rid="bibr34-0897190012451913">34</xref>
               </sup>
            </p>
         </sec>
         <sec id="section14-0897190012451913">
            <title>Implications for Pharmacologic Management and Perioperative Care</title>
            <p>Medications used in the treatment of BPH have notable adverse effects and monitoring parameters that require vigilance from the clinical pharmacist on the surgical floor. Perioperative and late complications consistently occur more often than intraoperative complications for TURP, HoLEP, and other MISTs, but these events may be prevented and managed with appropriate nursing care, careful monitoring, and drug therapy. The perioperative setting continues to present a need for the pharmacist’s vital role in optimizing outcomes for patients. <xref ref-type="table" rid="table4-0897190012451913">Table 4</xref> summarizes the implications for pharmacists and other health care providers.<sup>
                  <xref ref-type="bibr" rid="bibr4-0897190012451913">4</xref>,<xref ref-type="bibr" rid="bibr12-0897190012451913">12</xref>
                  <xref ref-type="bibr" rid="bibr13-0897190012451913"/>
                  <xref ref-type="bibr" rid="bibr14-0897190012451913"/>–<xref ref-type="bibr" rid="bibr15-0897190012451913">15</xref>,<xref ref-type="bibr" rid="bibr17-0897190012451913">17</xref>
                  <xref ref-type="bibr" rid="bibr18-0897190012451913"/>–<xref ref-type="bibr" rid="bibr19-0897190012451913">19</xref>,<xref ref-type="bibr" rid="bibr35-0897190012451913">35</xref>,<xref ref-type="bibr" rid="bibr36-0897190012451913">36</xref>
               </sup>
            </p>
            <table-wrap id="table4-0897190012451913" position="float">
               <label>Table 4.</label>
               <caption>
                  <p>Implications for Perioperative Care.<sup>a</sup>
                  </p>
               </caption>
               <graphic alt-version="no" alternate-form-of="table4-0897190012451913" position="float" xlink:href="10.1177_0897190012451913-table4.tif" xlink:type="simple"/>
               <table>
                  <thead>
                     <tr>
                        <th colspan="1" rowspan="1">Condition</th>
                        <th colspan="1" rowspan="1">Risks</th>
                        <th colspan="1" rowspan="1">Diagnostic factors</th>
                        <th colspan="1" rowspan="1">Actions needed</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td colspan="1" rowspan="1">Postprocedure bleeding</td>
                        <td colspan="1" rowspan="1">Risk of urethral bleeding after TURP or HoLEP is considerable and more common after TURP than HoLEP</td>
                        <td colspan="1" rowspan="1">
                           <list list-type="bullet">
                              <list-item>
                                 <p>Urine color</p>
                              </list-item>
                              <list-item>
                                 <p>Clots in urine</p>
                              </list-item>
                              <list-item>
                                 <p>Heart rate (tachycardia)</p>
                              </list-item>
                              <list-item>
                                 <p>Blood pressure (hypotension)</p>
                              </list-item>
                           </list>
                        </td>
                        <td colspan="1" rowspan="1">
                           <list list-type="bullet">
                              <list-item>
                                 <p>Contact surgical team</p>
                              </list-item>
                              <list-item>
                                 <p>Continue, restart, or adjust rate of the continuous bladder irrigation</p>
                              </list-item>
                              <list-item>
                                 <p>Monitor vital signs</p>
                              </list-item>
                              <list-item>
                                 <p>Encourage oral fluids</p>
                              </list-item>
                              <list-item>
                                 <p>Minimize activity</p>
                              </list-item>
                              <list-item>
                                 <p>Avoid straining in urination</p>
                              </list-item>
                              <list-item>
                                 <p>Consider laxative to prevent constipation and straining during bowel movements</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">AUR</td>
                        <td colspan="1" rowspan="1">AUR can occur postoperatively with TURP or HoLEP and may require recatheterization</td>
                        <td colspan="1" rowspan="1">
                           <list list-type="bullet">
                              <list-item>
                                 <p>Urine output</p>
                              </list-item>
                              <list-item>
                                 <p>Sensation of bladder fullness</p>
                              </list-item>
                              <list-item>
                                 <p>Presence of post void residual urine/bladder scan</p>
                              </list-item>
                              <list-item>
                                 <p>Color of urine</p>
                              </list-item>
                              <list-item>
                                 <p>Presence of sediment in urine</p>
                              </list-item>
                           </list>
                        </td>
                        <td colspan="1" rowspan="1">
                           <list list-type="bullet">
                              <list-item>
                                 <p>Encourage oral fluids</p>
                              </list-item>
                              <list-item>
                                 <p>Provide bladder/Foley catheter irrigation</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">UTI</td>
                        <td colspan="1" rowspan="1">Occurs more often in TURP than HoLEP, likely because TURP involves a longer indwelling catheter time but the cause may be multifactorial</td>
                        <td colspan="1" rowspan="1">
                           <list list-type="bullet">
                              <list-item>
                                 <p>Fever</p>
                              </list-item>
                              <list-item>
                                 <p>Shaking/chills</p>
                              </list-item>
                              <list-item>
                                 <p>Elevated leukocyte levels</p>
                              </list-item>
                              <list-item>
                                 <p>Heart rate (tachycardia)</p>
                              </list-item>
                              <list-item>
                                 <p>Blood pressure (hypotension)</p>
                              </list-item>
                           </list>
                        </td>
                        <td colspan="1" rowspan="1">
                           <list list-type="bullet">
                              <list-item>
                                 <p>Monitor for signs and symptoms of infection; may elicit early intervention, minimize complications, and increase quality of life</p>
                              </list-item>
                              <list-item>
                                 <p>3-day course of antibiotics (ie, trimethoprim sulfamethoxazole or ciprofloxacin) with antipyretic (ie, acetaminophen) generally is the most appropriate course of action</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Urgency/urge incontinence</td>
                        <td colspan="1" rowspan="1">May present postoperatively while patient is on surgical floor after any prostate surgery</td>
                        <td colspan="1" rowspan="1">
                           <list list-type="bullet">
                              <list-item>
                                 <p>Presence of urgency, urge incontinence</p>
                              </list-item>
                              <list-item>
                                 <p>Pain score</p>
                              </list-item>
                           </list>
                        </td>
                        <td colspan="1" rowspan="1">
                           <list list-type="bullet">
                              <list-item>
                                 <p>Belladonna and opium suppositories may be option for decreasing spasms and relieving associated pain</p>
                              </list-item>
                              <list-item>
                                 <p>Oxybutynin, an antagonist of acetylcholine at postganglionic muscarinic receptors, also acts by relaxing the smooth muscle of the bladder, decreasing spasms that promote urge incontinence</p>
                              </list-item>
                           </list>
                        </td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <fn id="table-fn10-0897190012451913">
                     <p>Abbreviations: AUR, acute urinary retention; HoLEP, Holmium laser enucleation of the prostate; TURP, transurethral resection of the prostate; UTI, urinary tract infection.</p>
                  </fn>
                  <fn id="table-fn11-0897190012451913">
                     <p>
                        <sup>a</sup> Data from Ahyai et al,<sup>
                           <xref ref-type="bibr" rid="bibr4-0897190012451913">4</xref>
                        </sup> Avodart,<sup>
                           <xref ref-type="bibr" rid="bibr12-0897190012451913">12</xref>
                        </sup> Proscar,<sup>
                           <xref ref-type="bibr" rid="bibr13-0897190012451913">13</xref>
                        </sup> Cardura,<sup>
                           <xref ref-type="bibr" rid="bibr14-0897190012451913">14</xref>
                        </sup> Hytrin,<sup>
                           <xref ref-type="bibr" rid="bibr15-0897190012451913">15</xref>
                        </sup> Uroxatral,<sup>
                           <xref ref-type="bibr" rid="bibr17-0897190012451913">17</xref>
                        </sup> Flomax,<sup>
                           <xref ref-type="bibr" rid="bibr18-0897190012451913">18</xref>
                        </sup> Rapaflo,<sup>
                           <xref ref-type="bibr" rid="bibr19-0897190012451913">19</xref>
                        </sup> Dirksen,<sup>
                           <xref ref-type="bibr" rid="bibr35-0897190012451913">35</xref>
                        </sup> and Nicolle.<sup>
                           <xref ref-type="bibr" rid="bibr36-0897190012451913">36</xref>
                        </sup>
                     </p>
                  </fn>
               </table-wrap-foot>
            </table-wrap>
         </sec>
      </sec>
   </body>
   <back>
      <fn-group>
         <fn fn-type="conflict" id="fn1-0897190012451913">
            <label>Declaration of Conflicting Interests</label>
            <p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
         </fn>
         <fn fn-type="financial-disclosure" id="fn2-0897190012451913">
            <label>Funding</label>
            <p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
         </fn>
      </fn-group>
      <ref-list>
         <title>References</title>
         <ref id="bibr1-0897190012451913">
            <label>1</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Bushman</surname>
                     <given-names>W</given-names>
                  </name>
               </person-group>. <article-title>Etiology, epidemiology, and natural history of benign prostatic hyperplasia</article-title>. <source>Urol Clin North Am</source>. <year>2009</year>;<volume>36</volume>(<issue>4</issue>):<fpage>403</fpage>–<lpage>415</lpage>.</citation>
         </ref>
         <ref id="bibr2-0897190012451913">
            <label>2</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Albertsen</surname>
                     <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Pellissier</surname>
                     <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Lowe</surname>
                     <given-names>FC</given-names>
                  </name>
                  <etal/>
               </person-group> 
               <article-title>Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study</article-title>. <source>Clin Ther</source>. <year>1999</year>;<volume>21</volume>(<issue>6</issue>):<fpage>1006</fpage>–<lpage>1024</lpage>.</citation>
         </ref>
         <ref id="bibr3-0897190012451913">
            <label>3</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>McVary</surname>
                     <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Roehrborn</surname>
                     <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Avins</surname>
                     <given-names>AL</given-names>
                  </name>
                  <etal/>
               </person-group> 
               <article-title>Update on AUA guideline on the management of benign prostatic hyperplasia</article-title>. <source>J Urol</source>. <year>2011</year>;<volume>185</volume>(<issue>5</issue>):<fpage>1793</fpage>–<lpage>1803</lpage>. <comment>Epub 2011 Mar 21</comment>.</citation>
         </ref>
         <ref id="bibr4-0897190012451913">
            <label>4</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Ahyai</surname>
                     <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gilling</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Kaplan</surname>
                     <given-names>SA</given-names>
                  </name>
                  <etal/>
               </person-group> 
               <article-title>Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement</article-title>. <source>Eur Urol</source>. <year>2010</year>;<volume>58</volume>(<issue>3</issue>):<fpage>384</fpage>–<lpage>397</lpage>. <comment>Epub 2010 Jun 11</comment>.</citation>
         </ref>
         <ref id="bibr5-0897190012451913">
            <label>5</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Reynard</surname>
                     <given-names>JM</given-names>
                  </name>
               </person-group>. <article-title>Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents?</article-title> 
               <source>Curr Opin Urol</source>. <year>2004</year>;<volume>14</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>16</lpage>.</citation>
         </ref>
         <ref id="bibr6-0897190012451913">
            <label>6</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Zhu</surname>
                     <given-names>YS</given-names>
                  </name>
               </person-group>, <article-title>Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate</article-title>. <source>Ann N Y Acad Sci</source>. <year>2009</year>;<volume>1155</volume>:<fpage>43</fpage>–<lpage>56</lpage>.</citation>
         </ref>
         <ref id="bibr7-0897190012451913">
            <label>7</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Stoner</surname>
                     <given-names>E</given-names>
                  </name>
               </person-group>. <article-title>The clinical development of a 5 alpha-reductase inhibitor, finasteride</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>1990</year>;<volume>37</volume>(<issue>3</issue>):<fpage>375</fpage>–<lpage>378</lpage>.</citation>
         </ref>
         <ref id="bibr8-0897190012451913">
            <label>8</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Lepor</surname>
                     <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Kazzazi</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Djavan</surname>
                     <given-names>B</given-names>
                  </name>
               </person-group>. <article-title>Alpha blockers for the treatment of benign prostatic hyperplasia: the new era</article-title>. <source>Curr Opin Urol</source>. <year>2012</year>;<volume>22</volume>(<issue>1</issue>):<fpage>7</fpage>–<lpage>15</lpage>.</citation>
         </ref>
         <ref id="bibr9-0897190012451913">
            <label>9</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>O’Brien</surname>
                     <given-names>WM</given-names>
                  </name>
               </person-group>. <article-title>Benign prostatic hypertrophy</article-title>. <source>Am Fam Physician</source>. <year>1991</year>;<volume>44</volume>(<issue>1</issue>):<fpage>162</fpage>–<lpage>171</lpage>.</citation>
         </ref>
         <ref id="bibr10-0897190012451913">
            <label>10</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Burnett</surname>
                     <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Wein</surname>
                     <given-names>AJ</given-names>
                  </name>
               </person-group>. <article-title>Benign prostatic hyperplasia in primary care: what you need to know</article-title>. <source>J Urol</source>. <year>2006</year>;<volume>175</volume>(<issue>3 pt 2</issue>):<fpage>S19</fpage>–<lpage>S24</lpage>.</citation>
         </ref>
         <ref id="bibr11-0897190012451913">
            <label>11</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Tom</surname>
                     <given-names>WC.</given-names>
                  </name>
               </person-group> 
               <article-title>Combination therapy for benign prostatic hyperplasia</article-title>. <source>Pharmacist’s Letter/Prescriber’s Letter</source>. <year>2008</year>;<volume>24</volume>(<issue>document 240806</issue>):<fpage>4</fpage>.</citation>
         </ref>
         <ref id="bibr12-0897190012451913">
            <label>12</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Avodart [package insert]</collab>. <publisher-loc>Research Triangle Park, NC</publisher-loc>: <publisher-name>GlaxoSmithKline</publisher-name>; <year>2010</year>.</citation>
         </ref>
         <ref id="bibr13-0897190012451913">
            <label>13</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Proscar [package insert]</collab>. <publisher-loc>Whitehouse Station, NJ</publisher-loc>: <publisher-name>Merck</publisher-name>; <year>2010</year>.</citation>
         </ref>
         <ref id="bibr14-0897190012451913">
            <label>14</label>
            <citation citation-type="book" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Cardura</surname>
                     <given-names>XL</given-names>
                  </name>
               </person-group> 
               <comment>[package insert]</comment>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Pfizer</publisher-name>; <year>2009</year>.</citation>
         </ref>
         <ref id="bibr15-0897190012451913">
            <label>15</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Hytrin [package insert]</collab>. <publisher-loc>North Chicago, IL</publisher-loc>: <publisher-name>Abbott</publisher-name>; <year>2009</year>.</citation>
         </ref>
         <ref id="bibr16-0897190012451913">
            <label>16</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Cardinal Health [Internet]</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.cardinal.com" xlink:type="simple">http://www.cardinal.com</ext-link>. <comment>Accessed February 9, 2011</comment>.</citation>
         </ref>
         <ref id="bibr17-0897190012451913">
            <label>17</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Uroxatral [package insert]</collab>. <publisher-loc>Bridgewater, NJ</publisher-loc>: <publisher-name>Sanofi-Synthelabo</publisher-name>; <year>2009</year>.</citation>
         </ref>
         <ref id="bibr18-0897190012451913">
            <label>18</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Flomax [package insert]</collab>. <publisher-loc>Ridgefield, CT</publisher-loc>: <publisher-name>Boehringer Ingelheim</publisher-name>; <year>2009</year>.</citation>
         </ref>
         <ref id="bibr19-0897190012451913">
            <label>19</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Rapaflo [package insert]</collab>. <publisher-loc>Corona, CA</publisher-loc>: <publisher-name>Watson</publisher-name>; <year>2009</year>.</citation>
         </ref>
         <ref id="bibr20-0897190012451913">
            <label>20</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Jalyn [package insert]</collab>. <publisher-loc>Research Triangle, NC</publisher-loc>: <publisher-name>GlaxoSmithKline</publisher-name>; <year>2011</year>.</citation>
         </ref>
         <ref id="bibr21-0897190012451913">
            <label>21</label>
            <citation citation-type="book" xlink:type="simple">
               <source>Red book: pharmacy’s fundamental reference</source>. <publisher-loc>Montvale, NJ</publisher-loc>: <publisher-name>Thomson PDF</publisher-name>; <year>c2010</year>.</citation>
         </ref>
         <ref id="bibr22-0897190012451913">
            <label>22</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Wurzel</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Ray</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Major-Walker</surname>
                     <given-names>K</given-names>
                  </name>
                  <etal/>
               </person-group> 
               <article-title>The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia</article-title>. <source>Prostate Cancer Prostatic Dis</source>. <year>2007</year>;<volume>10</volume>(<issue>2</issue>):<fpage>149</fpage>–<lpage>154</lpage>. <comment>Epub 2006 Dec 26</comment>.</citation>
         </ref>
         <ref id="bibr23-0897190012451913">
            <label>23</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>McConnell</surname>
                     <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Wilson</surname>
                     <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>George</surname>
                     <given-names>FW</given-names>
                  </name>
                  <etal/>
               </person-group> 
               <article-title>Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1992</year>;<volume>74</volume>(<issue>3</issue>):<fpage>505</fpage>–<lpage>508</lpage>.</citation>
         </ref>
         <ref id="bibr24-0897190012451913">
            <label>24</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Roehrborn</surname>
                     <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Siami</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Barkin</surname>
                     <given-names>J</given-names>
                  </name>
                  <etal/>
               </person-group> 
               <article-title>The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study</article-title>. <source>J Urol</source>. <year>2008</year>;<volume>179</volume>(<issue>2</issue>):<fpage>616</fpage>–<lpage>621</lpage>. <comment>Epub 2007 Dec 21</comment>.</citation>
         </ref>
         <ref id="bibr25-0897190012451913">
            <label>25</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Kaplan</surname>
                     <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Roehrborn</surname>
                     <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Rovner</surname>
                     <given-names>ES</given-names>
                  </name>
                  <etal/>
               </person-group> 
               <article-title>Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder</article-title>. <source>JAMA</source>. <year>2006</year>;<volume>296</volume>(<issue>19</issue>):<fpage>2319</fpage>–<lpage>2328</lpage>.</citation>
         </ref>
         <ref id="bibr26-0897190012451913">
            <label>26</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Athanasopoulos</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gyftopoulos</surname>
                     <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Giannitsas</surname>
                     <given-names>K</given-names>
                  </name>
                  <etal/>
               </person-group> 
               <article-title>Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study</article-title>. <source>J Urol</source>. <year>2003</year>;<volume>169</volume>(<issue>6</issue>):<fpage>2253</fpage>–<lpage>2256</lpage>.</citation>
         </ref>
         <ref id="bibr27-0897190012451913">
            <label>27</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Wasson</surname>
                     <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Reda</surname>
                     <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bruskewitz</surname>
                     <given-names>RC</given-names>
                  </name>
                  <etal/>
               </person-group> 
               <article-title>The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>332</volume>(<issue>2</issue>):<fpage>75</fpage>–<lpage>79</lpage>.</citation>
         </ref>
         <ref id="bibr28-0897190012451913">
            <label>28</label>
            <citation citation-type="web" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Cunningham</surname>
                     <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Kadmon</surname>
                     <given-names>D</given-names>
                  </name>
               </person-group>. <article-title>Surgical and other invasive therapies of benign prostate hyperplasia [Internet]</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.uptodate.com/contents/surgical-and-other-invasive-therapies-of-benign-prostatic-hyperplasia" xlink:type="simple">http://www.uptodate.com/contents/surgical-and-other-invasive-therapies-of-benign-prostatic-hyperplasia</ext-link>. <comment>Accessed March 6, 2011</comment>.</citation>
         </ref>
         <ref id="bibr29-0897190012451913">
            <label>29</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Lerner</surname>
                     <given-names>LB</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Tyson</surname>
                     <given-names>MD</given-names>
                  </name>
               </person-group>. <article-title>Holmium laser applications of the prostate</article-title>. <source>Urol Clin North Am</source>. <year>2009</year>;<volume>36</volume>(<issue>4</issue>):<fpage>485</fpage>–<lpage>495</lpage>.</citation>
         </ref>
         <ref id="bibr30-0897190012451913">
            <label>30</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Hawary</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Mukhtar</surname>
                     <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Sinclair</surname>
                     <given-names>A</given-names>
                  </name>
                  <etal/>
               </person-group> 
               <article-title>Transurethral resection of the prostate syndrome: almost gone but not forgotten</article-title>. <source>J Endourol</source>. <year>2009</year>;<volume>23</volume>(<issue>12</issue>):<fpage>2013</fpage>–<lpage>2020</lpage>.</citation>
         </ref>
         <ref id="bibr31-0897190012451913">
            <label>31</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Meyer</surname>
                     <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gillatt</surname>
                     <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Lush</surname>
                     <given-names>R</given-names>
                  </name>
                  <etal/>
               </person-group> 
               <article-title>Managing the warfarinized urological patient</article-title>. <source>BJU Int</source>. <year>2003</year>;<volume>92</volume>(<issue>4</issue>):<fpage>351</fpage>–<lpage>354</lpage>.</citation>
         </ref>
         <ref id="bibr32-0897190012451913">
            <label>32</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Douketis</surname>
                     <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Spyropoulos</surname>
                     <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Spencer</surname>
                     <given-names>FA</given-names>
                  </name>
                  <etal/>
               </person-group> 
               <article-title>Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines</article-title>. <source>Chest</source>. <year>2012</year>;<volume>141</volume>(<issue>2 suppl</issue>):<fpage>e326S</fpage>–<lpage>e350S</lpage>.</citation>
         </ref>
         <ref id="bibr33-0897190012451913">
            <label>33</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Elzayat</surname>
                     <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Habib</surname>
                     <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Elhilali</surname>
                     <given-names>M</given-names>
                  </name>
               </person-group>. <article-title>Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders</article-title>. <source>J Urol</source>. <year>2006</year>;<volume>175</volume>(<issue>4</issue>):<fpage>1428</fpage>–<lpage>1432</lpage>.</citation>
         </ref>
         <ref id="bibr34-0897190012451913">
            <label>34</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Forrest</surname>
                     <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Clemens</surname>
                     <given-names>JQ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Finamore</surname>
                     <given-names>P</given-names>
                  </name>
                  <etal/>
               </person-group>; <collab collab-type="author" xlink:type="simple">American Urological Association</collab>. <article-title>AUA Best Practice Statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery</article-title>. <source>J Urol</source>. <year>2009</year>;<volume>181</volume>(<issue>3</issue>):<fpage>1170</fpage>–<lpage>1177</lpage>. <comment>Epub January 18, 2009</comment>.</citation>
         </ref>
         <ref id="bibr35-0897190012451913">
            <label>35</label>
            <citation citation-type="book" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Dirksen</surname>
                     <given-names>SR</given-names>
                  </name>
               </person-group>. <article-title>Nursing management: male reproductive problems</article-title>. In: <person-group person-group-type="editor">
                  <name name-style="western">
                     <surname>Lewis</surname>
                     <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                     <surname>McLean</surname>
                     <given-names>Heitkemper M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Dirksen</surname>
                     <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Graber</surname>
                     <given-names>O’Brien PG</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bucher</surname>
                     <given-names>L</given-names>
                  </name>
               </person-group>, eds. <source>Medical-Surgical Nursing: Assessment and Management of Clinical Problems</source>. <edition>7th ed</edition>. <publisher-loc>St. Louis, MO</publisher-loc>: <publisher-name>Mosby Elsevier</publisher-name>; <year>2007</year>:<fpage>1414</fpage>–<lpage>1439</lpage>.</citation>
         </ref>
         <ref id="bibr36-0897190012451913">
            <label>36</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Nicolle</surname>
                     <given-names>LE</given-names>
                  </name>
               </person-group>. <article-title>Update in adult urinary tract infection</article-title>. <source>Curr Infect Dis Rep</source>. <year>2011</year>;<volume>13</volume>(<issue>6</issue>):<fpage>552</fpage>–<lpage>560</lpage>.</citation>
         </ref>
      </ref-list>
   </back>
</article>